We hypothesized that EMT transition and downregulation of the MUC16/CA125 target could be a potential mechanism of resistance in these cells; indeed, we found decreased CA125 expression in both M02 and M10 tumor cells (Fig. 1d) despite clinically increased CA125 in both patients (Fig. 1e). The gene discussed is MUC16; the disease is neoplasm.